Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Biotechnology company developing ultracompact genetic medicines using epigenetic engineering and CRISPR for serious diseases.
Epic-Bio is a South San Francisco, California-based biotechnology company that develops ultracompact therapies using epigenetic engineering to precisely modulate gene expression in vivo. The organization builds a therapeutic platform based on CRISPR innovations, specifically utilizing CasMINI, the smallest known Cas protein, to target the epigenome and create a new class of genetic medicines for serious diseases. The startup emerged from stealth operations in July 2022, supported by a $55 million Series A venture capital financing round that included investments from Horizons Ventures and other institutional backers. Under the operational leadership of Chief Executive Officer Amber Salzman, the enterprise focuses on advancing a preclinical development pipeline for conditions treatable via epigenetic editing, engaging in academic and industry partnerships to advance its genetic medicine applications. Epic-Bio was officially founded in 2019 by CRISPR pioneer Stanley Qi.
Epic-Bio has raised $123.0M across 2 funding rounds.
Epic-Bio has raised $123.0M in total across 2 funding rounds.
Epic-Bio has raised $123.0M in total across 2 funding rounds.
Epic-Bio's investors include Ally Bridge Group, Horizons Ventures.
Epic-Bio has raised $123.0M across 2 funding rounds. Most recently, it raised $68.0M Series B in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 26, 2025 | $68M Series B | Ally Bridge Group | — | Announced |
| Jul 12, 2022 | $55M Series A | Horizons Ventures | — | Announced |